Status:
UNKNOWN
Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients
Lead Sponsor:
Copenhagen University Hospital at Herlev
Conditions:
Rectum Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
response rate to adding cetuximab, oxaliplatin and capecitabine to radiation for advanced rectum cancer
Detailed Description
Dynamic MRI will be used to monitor the effect of the treatment and will be compared to pathologic results.
Eligibility Criteria
Inclusion
- advanced rectum cancer
Exclusion
- prior radiation
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2017
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00964457
Start Date
August 1 2009
End Date
July 1 2017
Last Update
August 25 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Herlev Hospital
Herlev, Denmark, 2730